Cargando…

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2

Indoleamine 2, 3-dioxygenase 1 (IDO1) is commonly expressed by cancers as a mechanism for evading the immune system. Preclinical and clinical studies have indicated the potential of combining IDO1 inhibitors with immune therapies for the treatment of cancer, strengthening an interest in the discover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tijono, Sofian M, Palmer, Brian D., Tomek, Petr, Flanagan, Jack U., Henare, Kimiora, Gamage, Swarna, Braun, Lukas, Ching, Lai-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501369/ https://www.ncbi.nlm.nih.gov/pubmed/36145311 http://dx.doi.org/10.3390/ph15091090

Ejemplares similares

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Comprehensive behavioral analysis of tryptophan 2,3‐dioxygenase (Tdo2) knockout mice
por: Hattori, Satoko, et al.
Publicado: (2018)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-dioxygenase 2 (TDO2)
por: Crosignani, Stefano, et al.
Publicado: (2014)

Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis
por: Lanz, Tobias V., et al.
Publicado: (2017)

Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
por: Kudo, Takumi, et al.
Publicado: (2020)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Identification and optimisation of next generation inhibitors of IDO1 and TDO
por: Wise, Alan, et al.
Publicado: (2015)

Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
por: Ye, Zixiang, et al.
Publicado: (2019)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Induction of TDO2 and IDO2 in Liver by High-Fat Feeding in Mice: Discrepancies with Human Obesity
por: Poulain-Godefroy, Odile, et al.
Publicado: (2013)

Organ Correlation with Tryptophan Metabolism Obtained by Analyses of TDO-KO and QPRT-KO Mice
por: Shibata, Katsumi, et al.
Publicado: (2016)

Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

Host cell depletion of tryptophan by IFNγ-induced Indoleamine 2,3-dioxygenase 1 (IDO1) inhibits lysosomal replication of Coxiella burnetii
por: Ganesan, Sandhya, et al.
Publicado: (2019)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
por: Peng, Xuerun, et al.
Publicado: (2022)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Exploring the mechanism of tryptophan 2,3-dioxygenase
por: Thackray, Sarah J., et al.
Publicado: (2008)

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)

IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
por: Sucher, Robert, et al.
Publicado: (2010)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
por: Xiao, Mei, et al.
Publicado: (2023)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Tryptophan-Restriction Diets Help to Maintain L-Tryptophan Homeostasis in Tryptophan 2,3-Dioxygenase Knockout Mice
por: Maeta, Akihiro, et al.
Publicado: (2013)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

IDO-induced immunosuppressive tryptophan catabolism following primary HIV infection
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

TDO Promotes Hepatocellular Carcinoma Progression
por: Li, Shanbao, et al.
Publicado: (2020)

Wideband TDoA Positioning Exploiting RSS-Based Clustering
por: Fuchs, Andreas, et al.
Publicado: (2023)

Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance
por: Hoffmann, Delia, et al.
Publicado: (2020)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
por: Zhang, Rongjie, et al.
Publicado: (2022)

Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through control of cell heme allocation by nitric oxide
por: Biswas, Pranjal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nof5g4u4u3kbdjmn7snnkoe5d1